These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24472480)

  • 21. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
    Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
    Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.
    Kim J; Han W; Jung SY; Park YH; Moon HG; Ahn SK; Lee JW; Kim MK; Kim JJ; Lee ES; You TK; Kang HS; Lee ES; Ro J; Lee JE; Nam SJ; Yim YH; Park IA; Noh DY
    Ann Surg Oncol; 2015 Oct; 22(11):3481-8. PubMed ID: 25652052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].
    Joubert C; Boissonneau S; Fina F; Figarella-Branger D; Ouafik L; Fuentes S; Dufour H; Gonçalves A; Charaffe-Jauffret E; Metellus P
    Neurochirurgie; 2016 Jun; 62(3):151-6. PubMed ID: 27236733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
    Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
    Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
    Popovska S; Ivanov I
    Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM; Atta IS; Wolff DJ; Self SE
    Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
    Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
    Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women.
    Yang WT; Dryden M; Broglio K; Gilcrease M; Dawood S; Dempsey PJ; Valero V; Hortobagyi G; Atchley D; Arun B
    Breast Cancer Res Treat; 2008 Oct; 111(3):405-10. PubMed ID: 18026834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).
    Thompson AM; Jordan LB; Quinlan P; Anderson E; Skene A; Dewar JA; Purdie CA;
    Breast Cancer Res; 2010; 12(6):R92. PubMed ID: 21059212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.